Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3475 and SBRT in Metastatic Melanoma or NSCLC
NCT02407171Phase 2Completed
- Sponsor
- Yale University
- Start
- Apr 2015
- Primary completion
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in melanoma, non-small cell lung cancer (NSCLC), sponsored by Yale University. Started Apr 2015; status: completed.
02
Drugs
03
Conditions
melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02407171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02407171.